Page 3 - Les meilleurs doctors traitant la maladie suivante : Cancer du foie stade 3 - TOP -87 des médecins

Le professeur agrégé Tahsin Ozatli est spécialisé dans les cancers du sein, du poumon et gastro-intestinaux à l'hôpital universitaire Istinye Liv.

• Plus de 10 ans d'expérience en oncologie
• Se spécialiser dans les cas de cancer complexes
• Travailler à la clinique d'oncologie d'Ankara et dans d'autres hôpitaux de premier plan
• Être promu au rang de professeur agrégé en 2016

Le professeur agrégé Dr Yusuf Acikgoz apporte son expertise de l'Ohio State University – il dirige désormais les cas d'oncologie à l'hôpital universitaire Lokman Hekim d'Ankara.

• Spécialisé en oncologie médicale avec plus de 7 ans de formation ciblée
• Participation à des essais cliniques internationaux de phase III pour des traitements avancés contre le cancer
• Maîtrise de l'anglais avec plusieurs certifications internationales
• Membre de l'American Society of Clinical Oncology

Le Dr Fox est spécialisé dans les traitements innovants du cancer du foie, combinant chimiothérapie, immunothérapie et thérapies ciblées.

• Médecin-chef au BKZ Solingen, un centre de cancérologie certifié
• Expert en diagnostic moléculaire et en plans de traitement personnalisés
• Membre actif de l'American Association for Cancer Research
• Impliqué dans la recherche sur la biologie moléculaire des maladies hémato-oncologiques

Le professeur Keil est spécialisé en radiologie diagnostique et interventionnelle avancée, y compris l'imagerie et le traitement du cancer du foie à l'Hôpital Académique de Solingen.

• Être diplômé avec mention de l'Université Julius-Maximilian de Wurtzbourg
• Être expert en techniques d'imagerie modernes telles que le scanner et l'IRM pour les interventions
• Occuper le poste de médecin-chef en radiologie à l'Hôpital Académique de Solingen
• Être formé sous la direction du célèbre professeur Rolf W. Günther à Aix-la-Chapelle

Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.

Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.

Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.

Spécialisé dans le traitement du cancer du foie avec une vaste expérience en oncologie médicale. Le Dr Ozden se concentre sur les soins personnalisés pour les patients atteints d'un cancer du foie de stade 3 à l'hôpital VM Medical Park Pendik.

• 6 ans de formation spécialisée en oncologie médicale à la faculté de médecine de l'université de Kocaeli
• Plus de 16 ans d'expérience en médecine interne et en oncologie
• Formé à la faculté de médecine Cerrahpaşa de l'université d'Istanbul, l'une des meilleures écoles de médecine de Turquie

Le Dr Alemdar est spécialisé dans le traitement du cancer du foie, avec un solide bagage académique et une vaste expérience hospitalière.

• Plus de 15 ans d'expérience en médecine interne et en oncologie
• Formation en oncologie médicale à la faculté de médecine de l'université d'Akdeniz
• Expérience au sein de plusieurs hôpitaux de premier plan en Turquie
• Membre de l'Association turque d'oncologie médicale

Le professeur agrégé Nail Paksoy est spécialisé dans le cancer du foie à l'hôpital Medipol Bahçelievler, avec des recherches approfondies en oncologie.

• Certifié par l'ESMO en oncologie médicale
• Participation active à des essais cliniques internationaux pour les traitements du cancer
• Publication de nombreux articles de recherche sur divers types de cancer
• Formation spécialisée (Fellowship) à l'Institut d'oncologie de l'Université d'Istanbul

Spécialisé en chirurgie laparoscopique avancée et oncologique dans les prestigieux hôpitaux de l'Université d'Istanbul. Pratique des techniques mini-invasives pour les cas complexes de cancer du foie.

• Certifié par le conseil de l'ordre avec plus de 30 ans d'expérience chirurgicale
• Formation spécialisée en chirurgie laparoscopique anti-reflux et bariatrique
• Fellowship avancé en techniques de chirurgie oncologique
• Réalisation d'interventions chirurgicales aux hôpitaux Büyük Anadolu

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Le professeur associé Babek Tabandeh est spécialisé dans la chirurgie du cancer du foie et les techniques mini-invasives à l'hôpital Medical Park Goztepe.

• Plus de 30 ans d'expérience en chirurgie générale
• Auteur de plus de 40 documents médicaux
• Membre de l'American College of Surgeons et de la Liver Transplantation Society
• Enseigne à la faculté de médecine de l'université Bahçeşehir

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Spécialisée en virothérapie – une approche d'immunothérapie de pointe pour le cancer du foie – le Dr Jaunalksne apporte plus de 30 ans d'expertise en immunologie.

• Responsable du centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Diplômée de l'Institut de médecine de Riga avec un internat en médecine interne
• Se concentrer sur les immunothérapies innovantes pour le traitement du cancer

Le Dr Auala Hubert dirige le centre des cancers gastro-intestinaux au centre médical Hadassah, avec 33 ans d'expérience en oncologie et radiothérapie.

• Se spécialiser en oncologie médicale et radiothérapie pour le cancer du foie
• Médecin senior au département d'oncologie de l'hôpital universitaire Hadassah
• Formation à l'Université hébraïque et à l'hôpital universitaire Hadassah
• Membre de l'Israel Society of Clinical Oncology et de la Cancer Association

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.